The UC Davis Cancer Center Biorepository was created in 2004 to provide quality cancer-related human biospecimens that are procured, stored and annotated using international standards of best practices and protocols that are Office for Human Research Protection (OHRP) compliant. The biorepository functions as a centralized tissue bank that provides all cancer center members with an efficient, high quality, stable, reliable, cost-effective access to cancer-related specimens and histology services.
The specific aims of the Biorepository shared resource are: The primary objectives of the CCB shared resource are to facilitate cancer related research at UC Davis by 1 procuring, preparing, storing and dispersing human cancer-related biospecimens from a centralized cancer center biorepository; 2 providing pathological and clinical annotated data using a secure database (caTissue) 3 ensuring compliance with all mandated regulatory processes (HHS, IRB, HIPAA, SRC) thereby promoting ethical research by UC Davis researchers; 4 providing experienced pathologic consultation to investigators 5 efficiently prioritizing, tracking and dispersing biospecimen requests via a rapid, web-based approval and monitoring process 6 providing Tissue Microarray (TMA) construction and histology services for Cancer Center investigators The long-term objective of the CCSR is to facilitate scientific interactions and enhance scientific productivity by providing well-characterized, high-quality cancer-related specimens with annotated data for clinical and basic science research purposes.

Public Health Relevance

The resource provides tissue in various forms of storage as well as bodily fluids that are used in basic cancer research and in animal models of cancer to improve scientific understanding of tumors, tumor development, and anti-tumor therapies with benefit, ultimately, to how cancer patients are treated and cured of disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-12
Application #
8743649
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
12
Fiscal Year
2014
Total Cost
$148,915
Indirect Cost
$51,894
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Braithwaite, Dejana; Miglioretti, Diana L; Zhu, Weiwei et al. (2018) Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. JAMA Intern Med 178:494-501
Unger, Jakob; Sun, Tianchen; Chen, Yi-Ling et al. (2018) Method for accurate registration of tissue autofluorescence imaging data with corresponding histology: a means for enhanced tumor margin assessment. J Biomed Opt 23:1-11
Wang, Guobao; Corwin, Michael T; Olson, Kristin A et al. (2018) Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. Phys Med Biol 63:155004
Winer, Rachel L; Tiro, Jasmin A; Miglioretti, Diana L et al. (2018) Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials 64:77-87
Withers, Sita S; Skorupski, Katherine A; York, Daniel et al. (2018) Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Vet Comp Oncol :
Floc'h, Nicolas; Martin, Matthew J; Riess, Jonathan W et al. (2018) Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther 17:885-896
Shih, Tsung-Chieh; Liu, Ruiwu; Wu, Chun-Te et al. (2018) Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. Clin Cancer Res 24:4319-4331
Weiss, Robert H (2018) Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol 38:175-182
Hegde, John V; Shaverdian, Narek; Daly, Megan E et al. (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer 124:521-529
Arun, Adith S; Tepper, Clifford G; Lam, Kit S (2018) Identification of integrin drug targets for 17 solid tumor types. Oncotarget 9:30146-30162

Showing the most recent 10 out of 836 publications